|
Dr. Chan leads healthcare and life science investments for the NJTC Venture Fund, an $80M early stage venture capital fund focused on New Jersey and the surrounding regions. He currently sits as a board director at portfolio companies Andrew Technologies, and is a board observer at Sword Diagnostics, InstaMed, and IntraCellular Therapies. Dr. Chan received his MD and PhD in Genetics from the Yale University School of Medicine. He completed his internal medicine residency at the Beth Israel Deaconess Medical Center at Harvard and is board-certified by the American Board of Internal Medicine. He also holds a BS in cell and molecular biology from Cornell University, graduating with honors and distinction. | 